Back to Browse Journals » Drug, Healthcare and Patient Safety » Volume 3

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis

Authors Lewiecki EM

Published Date December 2011 Volume 2011:3 Pages 79—91

DOI http://dx.doi.org/10.2147/DHPS.S7727

Published 1 December 2011

E Michael Lewiecki
New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA

Abstract: Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the principal regulator of osteoclastic bone resorption. Postmenopausal osteoporosis (PMO) is a systemic skeletal disease associated with high levels of RANKL, resulting in a high rate of bone remodeling and an imbalance of bone resorption over bone formation. By inhibiting RANKL in women with PMO, denosumab reduces the rate of bone remodeling, thereby increasing bone mineral density, improving bone strength, and reducing the risk of fractures. In clinical trials of women with osteoporosis and low bone mineral density, denosumab has been well tolerated, with overall rates of adverse events and serious adverse events in women treated with denosumab similar to those receiving placebo. In the largest clinical trial of denosumab for the treatment of women with PMO, there was a significantly greater incidence of cellulitis reported as a serious adverse event, with no difference in the overall incidence of cellulitis, and a significantly lower incidence of the serious adverse event of concussions with denosumab compared with placebo. The evidence supports a favorable balance of benefits versus risks of denosumab for the treatment of PMO. Assessments of the long-term safety of denosumab are ongoing. Denosumab 60 mg subcutaneously every 6 months is an approved treatment for women with PMO who are at high risk for fracture.

Keywords: denosumab, osteoporosis, safety, risk, benefit, FDA

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis

E Michael Lewiecki

Therapeutics and Clinical Risk Management 2009, 5:817-827

Published Date: 14 October 2009

Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect

E Michael Lewiecki

Core Evidence 2009, 4:13-23

Published Date: 18 June 2009

Denosumab: an investigational drug for the management of postmenopausal osteoporosis

E Michael Lewiecki

Biologics: Targets and Therapy 2008, 2:645-653

Published Date: 4 August 2008

Readers of this article also read:

Non-small cell lung cancer therapy: safety and efficacy in the elderly

Glotzer OS, Fabian T, Chandra A, Bakhos CT

Drug, Healthcare and Patient Safety 2013, 5:113-121

Published Date: 22 April 2013

Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics

Liu L, Ma Y, Wang RL, Xu WR, Wang SQ, Chou KC

Drug Design, Development and Therapy 2013, 7:279-288

Published Date: 8 April 2013

Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy

Frati F, Incorvaia C, David M, Scurati S, Seta S, Padua G, Cattaneo E, Cavaliere C, Di Rienzo A, Dell'Albani I, Puccinelli P

Drug Design, Development and Therapy 2012, 6:117-123

Published Date: 18 May 2012

Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates

Muratore M, Quarta E, Grimaldi A, Calcagnile F, Quarta L

Drug Design, Development and Therapy 2011, 5:445-454

Published Date: 19 October 2011

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma

Jain S, Diefenbach C, Zain J, O'Connor OA

Core Evidence 2011, 6:43-57

Published Date: 4 April 2011

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Structure-based design of anticancer prodrug PABA/NO

Xinhua Ji, Ajai Pal, Ravi Kalathur, Xun Hu, Yijun Gu, et al

Drug Design, Development and Therapy 2008, 2:123-130

Published Date: 11 August 2008